Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Company Overview

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $1.66 to $1.73
• 50-Day Range: N/A
• 52-Week Range: $1.12 to $4.20
• Volume: 75,322 shs
• Average Volume: 96,632 shs
• Market Capitalization: $127.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Inhibikase Therapeutics Stock Analysis - MarketRank™

Inhibikase Therapeutics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Inhibikase Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Inhibikase Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.41% of the outstanding shares of Inhibikase Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Inhibikase Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Inhibikase Therapeutics has recently increased by 8.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibikase Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibikase Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.41% of the outstanding shares of Inhibikase Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Inhibikase Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Inhibikase Therapeutics has recently increased by 8.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Inhibikase Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.22 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Inhibikase Therapeutics this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for IKT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of Inhibikase Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

IKT Stock Analysis - Frequently Asked Questions

How have IKT shares performed this year?

Inhibikase Therapeutics' stock was trading at $1.80 at the beginning of the year. Since then, IKT shares have decreased by 5.0% and is now trading at $1.71.

When did Inhibikase Therapeutics IPO?

Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IKT
• CIK: 1750149
• Web: N/A
• Phone: (678) 392-3419
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.82%
• Return on Assets: -58.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.09
• Quick Ratio: 10.09

Sales & Book Value

• Annual Sales: $260 thousand
• Price / Sales: 490.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 74,520,000
• Free Float: 69,077,000
• Market Cap: $127.43 million
• Optionable: N/A
• Beta: 0.92